This content is machine translated Non-small cell lung cancer Management of locally advanced NSCLC – where are we heading? Lung cancer is the second most common and deadliest type of cancer worldwide. Clinically, non-small cell lung cancer (NSCLC) is the most common pathologic form of lung cancer; approximately one-third…
View Post 3 min This content is machine translated Colon Cancer New therapeutic perspectives raise hope for improved overall survival This year’s ASCO brought exciting study results to light. Especially in tumors of the upper and lower gastrointestinal tract, there were developments, some of which had practice-changing potential. In metastatic colon cancer,…
View Post 4 min This content is machine translated Non-resectable BRAF-mutated melanoma 5-year data from COLUMBUS study support continued long-term benefits After five years of follow-up in the COLUMBUS study, it is clear that patients with non-resectable or metastatic melanoma with a BRAFV600 mutation benefit long-term from encorafenib in combination with…
View Post 4 min This content is machine translated BRAFV600E-mutated metastatic colorectal cancer (mCRC). Evidence for additional benefit of dual blockade An expert panel finds considerable added benefit in the dual-blockade encorafenib combined with cetuximab in the treatment of metastatic colorectal cancer with BRAFV600E mutation after prior systemic therapy. This is…
View Post 5 min This content is machine translated Non-resectable BRAF-mutated melanoma Update COLUMBUS study: BRAF/MEK inhibition has long-lasting effect For almost two years, an effective therapeutic option has been available for patients with non-resectable or metastatic BRAFV600-mutated melanoma with the combination of encorafenib plus binimetinib. An analysis of the…
View Post 3 min This content is machine translated Colorectal Cancer Focus on combination therapies Triple for colorectal cancer – for the first time, studies have shown clear superiority of a triple combination of encorafenib, binimetinib and cetuximab in progressive metastatic colorectal tumors.
View Post 7 min This content is machine translated Advanced training course in clinical oncology in St. Gallen Metastatic colorectal cancer “beyond surgery”. At the advanced training course in clinical oncology in St. Gallen, there was also a symposium on colorectal carcinoma, among other topics. In an overview, Prof. Dr. med. Ralf-Dieter Hofheinz,…
View Post 4 min This content is machine translated 25th EADV Congress in Vienna Progress in melanoma treatment: more success with combination therapies Just a few years ago, metastatic melanoma was rapidly fatal – but today the disease responds frequently and long-term to new drug therapies. Experts reported on advances in melanoma therapy…
View Post 15 min This content is machine translated Focus - Skin Cancer Malignant Melanoma, Targeted Therapy and Immunotherapy – The Road to Success Thanks to the approval of new therapeutic approaches, the treatment of advanced melanoma has been further developed in recent years. Patients with metastatic melanoma who undergo immunotherapy and/or targeted therapy…
View Post 11 min This content is machine translated From chemotherapy to immunotherapy Current system therapy in metastatic non-small cell lung cancer. Detailed molecular diagnosis is now mandatory for non-small cell lung cancer (NSCLC). In the presence of a driver mutation, the corresponding tyrosine kinase inhibitor should be used in the first…
View Post 6 min This content is machine translated European Lung Cancer Conference Mutation analysis is crucial for the choice of therapy Three interesting studies were presented at the European Lung Cancer Conference in Geneva. Two were dedicated to the group of NSCLC patients with an EGFR-activating mutation. Can erlotinib neoadjuvant achieve…
